Haldol Lactate is the brand-name intramuscular (IM) injectable form of haloperidol, a first-generation antipsychotic that has been in clinical use since the late 1950s. The “lactate” in the name refers to the salt form of the drug: haloperidol is combined with lactic acid to make it water-soluble enough for injection. This distinguishes it from Haldol Decanoate, a different injectable formulation designed for slow, long-acting release over weeks. Haldol Lactate is the fast-acting version, typically reaching peak blood levels within about 20 minutes of an IM injection, and it remains one of the most widely used medications for managing acute agitation in emergency departments, psychiatric units, and hospitals worldwide.
What Haldol Lactate Is For
The primary approved indication is acute psychotic agitation, particularly in patients with schizophrenia, acute mania, or other conditions causing severe behavioral disturbance. When someone is dangerously agitated and oral medication is refused or impractical, Haldol Lactate provides rapid sedation without the deep respiratory suppression that comes with some alternatives. Haloperidol works mainly by blocking dopamine D2 receptors in the brain, which reduces the psychotic symptoms and hyperarousal driving the agitation.1PubMed Central. Ketamine Versus Haloperidol/Lorazepam/Diphenhydramine Combination Treatment for Management of Acute Agitation in the Emergency Department
In practice, though, the drug is used far beyond formal psychiatric emergencies. It shows up in emergency departments for agitation of all causes, in intensive care units for delirium, in palliative care for nausea and terminal restlessness, and even in cases of severe vomiting tied to cannabis use. That breadth of use is unusual for an antipsychotic and reflects how comfortable clinicians have become with haloperidol’s predictable, well-understood pharmacology over more than six decades.
A Brief History
Haloperidol was synthesized on February 11, 1958, by Paul Janssen’s pharmaceutical team in Belgium. The name itself comes from the two halogen atoms in its molecular structure. Clinical trials at the University of Liège confirmed its effectiveness in acute and chronic psychosis, mania, and treatment-resistant schizophrenia, and it was licensed in Belgium under the brand name Haldol in October 1959.2PubMed. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice It reached the United States market in 1967. The lactate injectable formulation followed as clinicians needed a rapid-onset option for patients who could not or would not take pills. Decades later, Haldol Lactate remains on the World Health Organization’s List of Essential Medicines.
The B52 Cocktail and Emergency Agitation
If you spend any time in an emergency department, you will hear the term “B52.” It refers to a combination of three drugs given together by IM injection: Benadryl (diphenhydramine, typically 50 mg), “five of Haldol” (haloperidol 5 mg), and “two of Ativan” (lorazepam 2 mg). The rationale is that haloperidol blocks dopamine receptors to address psychotic agitation, lorazepam enhances the brain’s natural calming signals to relieve anxiety and produce sedation, and diphenhydramine adds sedation while also reducing the risk of muscle-stiffening side effects from haloperidol.3PubMed Central. Ketamine Versus Haloperidol/Lorazepam/Diphenhydramine Combination Treatment for Management of Acute Agitation in the Emergency Department
The cocktail is deeply entrenched in emergency medicine culture, but recent evidence has questioned whether the diphenhydramine component actually adds anything meaningful. A multicenter retrospective study compared the full B52 to just haloperidol plus lorazepam (the “52”) and found no significant difference in how often patients needed additional sedation. The two-drug combination was actually associated with a shorter length of stay, fewer episodes of low blood pressure, and fewer patients needing physical restraints compared to the three-drug B52.4PubMed. Efficacy of Combination Haloperidol, Lorazepam, and Diphenhydramine vs. Combination Haloperidol and Lorazepam in the Treatment of Acute Agitation: A Multicenter Retrospective Cohort Study Patients who received only the two-drug version were more likely to need an anticholinergic medication within two days, but none of them actually developed documented movement side effects. This has prompted some emergency physicians to drop the diphenhydramine, though both versions remain in common use.
How It Compares to Newer Intramuscular Antipsychotics
Haldol Lactate is a first-generation (“typical”) antipsychotic, and over the past two decades, IM formulations of newer (“atypical”) antipsychotics like olanzapine, ziprasidone, and aripiprazole have entered the market. The obvious question is whether the newer agents are better.
On raw effectiveness, the answer is that they are broadly comparable. A review of the available trial evidence found that the rapidly-acting IM atypical antipsychotics have similar efficacy to IM haloperidol for managing acute agitation.5PubMed. The comparative efficacy of intramuscular antipsychotics for the management of acute agitation Where the newer drugs pull ahead is side effects, specifically movement-related ones. In a double-blind trial comparing IM olanzapine and IM haloperidol in acutely agitated people with schizophrenia, both drugs reduced agitation significantly more than placebo, but olanzapine worked faster in the first 15 to 45 minutes. No patients on IM olanzapine developed acute dystonia, compared to about 7% of those on haloperidol.6PubMed. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia
A dose-response study reinforced this pattern: treatment-emergent parkinsonism occurred in roughly 17% of patients given IM haloperidol but in 0% to 3% of those given IM olanzapine at various doses.7JAMA Psychiatry. A Double-blind, Placebo-Controlled Dose-Response Comparison of Intramuscular Olanzapine and Haloperidol in the Treatment of Acute Agitation in Schizophrenia Despite these differences, Haldol Lactate retains widespread use for several practical reasons: it is cheap, available almost everywhere, can be mixed in the same syringe with lorazepam, and clinicians have decades of dosing experience with it. Cost and availability matter enormously in emergency settings, and haloperidol’s disadvantages can often be managed.
Movement Side Effects and How They Are Handled
The most common side effects that concern clinicians giving Haldol Lactate are extrapyramidal symptoms, a group of involuntary movement problems caused by dopamine blockade in the brain’s motor pathways. These include dystonia (sudden, sustained muscle contractions, often in the neck or jaw), akathisia (an intensely uncomfortable inner restlessness), and parkinsonism (stiffness, shuffling gait, tremor). Among patients who have never taken an antipsychotic before, these effects can be quite common and show up at similar rates regardless of whether haloperidol or a drug like risperidone is used.8PubMed. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone
Dystonia is the most dramatic and frightening of these, sometimes involving the eyes rolling upward or the throat muscles clenching. Fortunately, it responds rapidly to treatment. Benztropine, an anticholinergic medication, can be given intravenously; most patients improve within five minutes and are symptom-free by 15 minutes.9Australian Prescriber. The management of acute dystonic reactions Some clinicians give benztropine routinely alongside haloperidol as a preventive measure. A double-blind trial found that prophylactic benztropine lowered the dystonia rate from about 33% to 14%, consistent with the broader literature showing that anticholinergic prophylaxis works, though it adds side effects like dry mouth.10Journal of Clinical Psychopharmacology. The Effect of Benztropine on Haloperidol-Induced Dystonia, Clinical Efficacy and Pharmacokinetics: A Prospective, Double-Blind Trial
Interestingly, when haloperidol is given intravenously rather than intramuscularly, extrapyramidal symptoms appear to be much less common. A systematic review of IV haloperidol use found that these motor side effects, as well as more serious complications like neuroleptic malignant syndrome, were relatively rare with the IV route.11PubMed. Intravenous haloperidol: A systematic review of side effects and recommendations for clinical use The reasons for this difference are not entirely settled, but may relate to how quickly the drug reaches the brain and how blood levels rise with each route.
Cardiac Risk With Intravenous Use
One critical distinction between Haldol Lactate given intramuscularly and haloperidol given intravenously is cardiac safety. Although IV haloperidol is widely used in hospital settings, particularly in ICUs, it carries a risk of prolonging the QT interval on an electrocardiogram. A prolonged QT interval can trigger a dangerous heart rhythm called torsades de pointes, which can be fatal. Case reports have documented this occurring even in patients without prior heart problems. One well-described case involved a 41-year-old woman who developed torsades de pointes 55 minutes after an IV dose of 80 mg haloperidol, with her QT interval stretching to 610 milliseconds, well into the danger zone.12PubMed. Haloperidol-induced torsade de pointes
It is worth noting that the total cumulative dose in that case was enormous, 915 mg over seven days. Most clinical doses are far lower. But the case illustrates why IV haloperidol generally requires cardiac monitoring, and why the FDA has never formally approved haloperidol for IV use, even though off-label IV use is standard practice in many ICUs. Haldol Lactate was designed and approved for the IM route, which does not carry the same degree of QT risk.
Neuroleptic Malignant Syndrome
The most feared adverse reaction to any antipsychotic is neuroleptic malignant syndrome, or NMS: a combination of high fever, severe muscle rigidity, altered consciousness, and unstable blood pressure and heart rate. It can be fatal if not recognized quickly. NMS is more commonly associated with older antipsychotics like haloperidol than with newer ones, and the central mechanism involves profound blockade of D2 dopamine receptors. The syndrome is not strictly dose-dependent, but higher doses and rapid dose escalation are recognized risk factors.13Toxicology Reports. Neuroleptic malignant syndrome after overdose of haloperidol – A case report
Case reports continue to highlight how NMS can emerge in unexpected clinical scenarios. One recent case described a 58-year-old woman who developed NMS after hip surgery. She had received multiple doses of haloperidol for postoperative agitation while also continuing paroxetine, an antidepressant that can interact with haloperidol’s metabolism.14PubMed Central. Haloperidol-Induced Neuroleptic Malignant Syndrome: A Case Report The overlapping use of drugs that compete for the same liver enzymes likely contributed by pushing haloperidol levels higher than intended, which leads to the next important consideration.
How the Body Breaks Down Haloperidol
Haloperidol is metabolized primarily in the liver through several pathways. The most important enzyme systems involved are CYP3A4 and CYP2D6, both members of the cytochrome P450 family. CYP3A4 handles the largest share of the work, converting haloperidol into several metabolites. CYP2D6 also contributes, particularly to certain oxidation and dealkylation steps.15PubMed Central. Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol
This matters for drug interactions. Medications that strongly inhibit CYP3A4 or CYP2D6 can slow down haloperidol breakdown, raising blood levels and increasing side effect risk. Conversely, drugs that rev up these enzymes, like the anti-seizure medications carbamazepine and phenytoin or the antibiotic rifampin, can speed haloperidol clearance and reduce its effectiveness. A pharmacokinetics review lists interactions with fluoxetine, fluvoxamine, nefazodone, venlafaxine, quinidine, and several other common medications.16PubMed. Pharmacokinetics of haloperidol: an update
People also differ genetically in how active their CYP2D6 enzyme is. A prospective study of 172 psychiatric inpatients found that blood levels of haloperidol and its metabolite varied widely between individuals, and that these differences correlated with the number of active CYP2D6 gene copies a person carried.17PubMed. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment In practical terms, someone who is a “poor metabolizer” at CYP2D6 might experience much higher drug levels at a standard dose, raising the risk of side effects including those dangerous movement problems. Genetic testing for CYP2D6 status is available but not routinely performed before haloperidol is given, particularly in emergency situations where Haldol Lactate is most often used.
ICU Delirium and the Limits of Haloperidol
For years, haloperidol was the default drug for managing delirium in critically ill patients. It made intuitive sense: delirium involves disorganized thinking and agitation, haloperidol calms agitation and blocks dopamine, and earlier observational data hinted at benefit. But when rigorous randomized trials finally tested whether haloperidol actually resolves ICU delirium faster or improves outcomes, the results were sobering.
The Hope-ICU trial, a double-blind placebo-controlled study, found that patients given IV haloperidol spent roughly the same number of days alive without delirium or coma as patients given placebo.18The Lancet. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial The EuRIDICE trial was stopped early for futility after enrolling 132 patients, finding no increase in delirium- and coma-free days with haloperidol. One secondary finding was that haloperidol-treated patients needed fewer benzodiazepines, suggesting some symptomatic benefit even though the primary outcome did not budge.19PubMed Central. Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial
A larger Dutch trial published in the New England Journal of Medicine found that at 90 days, patients who received haloperidol averaged about 36 days alive and out of the hospital compared with 33 days in the placebo group, a difference that was not statistically significant. There was a suggestive trend toward lower 90-day mortality in the haloperidol group (about 36% versus 43%), but the confidence interval crossed zero, meaning the finding could have been due to chance.20PubMed. Haloperidol for the Treatment of Delirium in ICU Patients Taken together, these trials tell a consistent story: haloperidol can manage agitation symptoms in the ICU, but it does not clearly shorten the duration of delirium itself or improve hard outcomes. The drug treats the surface disturbance, not the underlying brain dysfunction.
Cannabis Hyperemesis Syndrome
One of the more surprising recent applications of haloperidol is for cannabis hyperemesis syndrome, a condition of severe, recurrent vomiting that develops in some heavy cannabis users. It responds poorly to standard anti-nausea medications, and emergency physicians often cycle through multiple drugs without success. The observation that haloperidol works for this condition started as case reports and has since been supported by trial data.21PubMed Central. Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?
The HaVOC trial, a randomized controlled study, compared IV haloperidol to ondansetron (a standard anti-nausea drug widely known by its brand name Zofran) in patients presenting to the emergency department with cannabis-associated vomiting. Haloperidol produced significantly greater improvement in symptoms. Patients who received haloperidol also used fewer rescue anti-nausea medications and left the emergency department on average about two and a half hours sooner than those given ondansetron.22PubMed. Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial That time difference is meaningful both for patient comfort and for emergency department throughput. The mechanism likely relates to haloperidol’s dopamine blockade in the brainstem’s vomiting center, a pathway that ondansetron, which targets serotonin receptors, does not affect as directly.
Palliative Care Uses
In hospice and palliative care, haloperidol fills several roles. Dopamine plays a part in the nausea pathways of the brain, and blocking it with haloperidol can relieve nausea and vomiting from causes as varied as opioid medications, bowel obstruction, and metabolic disturbances in advanced illness.23PubMed. Role of haloperidol in palliative medicine: an update It is also used for terminal agitation and delirium in dying patients, where the goal shifts from curing the underlying condition to relieving distress. In a study of frail older patients receiving pharmacological treatment for terminal agitation, delirium, and anxiety, a small percentage of patients received haloperidol specifically for nausea rather than psychiatric symptoms, underscoring its versatility in end-of-life care.24PubMed Central. Pharmacological Treatment for Terminal Agitation, Delirium and Anxiety in Frail Older Patients
In palliative settings, haloperidol is often preferred over newer antipsychotics because it can be given by multiple routes (oral, IM, IV, and even subcutaneously), it has minimal sedation at low doses, and it does not lower blood pressure as much as some alternatives. For a dying patient who can no longer swallow, the ability to give the drug by injection without needing IV access is a practical advantage that directly shapes care.
Pregnancy, Lactation, and Special Populations
Haloperidol crosses the placenta, and some early reports linked first-trimester exposure to limb reduction defects. Animal studies have also shown evidence of harm to developing embryos.25PubMed Central. The potential risks of commonly prescribed antipsychotics: during pregnancy and lactation However, the picture is not straightforward. Broader reviews have noted that while individual malformations have been reported, including cardiac anomalies with third-trimester exposure, none of these have reached statistical significance compared to the general population.26Journal of Alcoholism & Drug Dependence. Safety and Efficacy of Antipsychotics in Pregnancy and Lactation A separate review similarly concluded that no definitive association has been established between antipsychotic use and an increased risk of birth defects.27Current Women’s Health Reviews. Antipsychotic Medication (Safety/Risk) during Pregnancy and Breastfeeding
For breastfeeding, haloperidol is secreted in breast milk at very low concentrations, generally considered insufficient to cause harm to the infant.28Journal of Alcoholism & Drug Dependence. Safety and Efficacy of Antipsychotics in Pregnancy and Lactation As with all medications during pregnancy and nursing, the decision involves weighing the risks of the drug against the risks of untreated severe psychiatric illness, which itself carries significant dangers for both mother and child.
In elderly patients with dementia-related agitation, all antipsychotics, including haloperidol, carry an FDA black box warning about increased mortality risk. This has led to more cautious prescribing in nursing home settings, though haloperidol continues to be used when agitation poses an immediate safety threat and non-pharmacological interventions have failed.
Why Haldol Lactate Persists
It is worth asking why a drug developed in the 1950s, with a well-documented side effect profile that newer agents improve upon, still occupies such a central role in acute medicine. Part of the answer is economics. Generic haloperidol lactate is inexpensive, costing a fraction of what IM olanzapine or ziprasidone costs per dose. In emergency departments that manage thousands of agitated patients a year, that cost difference adds up. Part of the answer is familiarity and predictability. Clinicians know exactly what a 5 mg IM dose of haloperidol will do, how fast it will work, and what problems to watch for. And part of the answer is that the side effect gap, while real, is manageable. A dystonic reaction from haloperidol is frightening but usually reverses within minutes with benztropine. Newer agents avoid that scenario more often, but they bring their own concerns, such as olanzapine’s potential to cause excessive sedation, particularly when combined with benzodiazepines.
In high-income settings with good drug availability, the trend has been gradually shifting toward IM atypical antipsychotics as first-line agents for acute agitation. In lower-resource settings, and in clinical situations where haloperidol’s specific properties are wanted, such as palliative care or cannabinoid hyperemesis, it remains the go-to option. The drug’s remarkable longevity reflects not nostalgia, but the fact that it fills its role reliably, cheaply, and with risks that experienced clinicians know how to handle.